NCT04538066已完成2 期
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing Safety, Tolerability and Long-term Efficacy of Bryostatin in the Treatment of Moderately Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 122
- 试验地点
- 19
- 主要终点
- Safety: Treatment-emergent Adverse Events and Serious Adverse Events for All Randomized Subjects Who Received Any Study Medication
研究概览
简要总结
To evaluate the safety, tolerability, and long-term efficacy of bryostatin 1 (hereafter referred to as bryostatin) for the treatment of moderately severe Alzheimer's disease (AD).
详细描述
This is a randomized double-blind placebo-controlled, Phase 2 study comparing bryostatin-1 to placebo for long-term efficacy in the treatment of moderately severe AD (Mini Mental State Examination, 2nd edition scores of 10-18 at baseline) in the absence of memantine. Eligible subjects will receive 7 doses of bryostatin (i.v., 20μg) or matching placebo during the first 12 weeks. A second course of treatment consisting of 7 doses will begin 30 days after the final dose of the first treatment period. Cognitive tests will be assessed at intervals during the study and 4 months after the final dose of study drug. The primary endpoint is the total SIB score assessment obtained at Week 28, following completion of 2 courses of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Sponsor, investigators and staff, and the clinical research organization are all blinded to study treatment assignment.
入排标准
- 年龄范围
- 55 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent from caregiver and subject (if possible) or legally acceptable representative if different from caregiver
- •Male and female subjects 55-85 years of age inclusive
- •Cognitive deficit present for at least 2 years that meet the diagnostic criteria for probable Alzheimer's dementia. The diagnosis must be confirmed at the time of the screening visit
- •MMSE-2 score of 10-18 inclusive (applies to Screening Visit only)
- •Patients must have a baseline SIB total score of at least 60 and may not have a SIB score >93 at screening
- •Neuroimaging computerized tomography (CT) or Magnetic Resonance Imaging (MRI) within the last 24 months consistent with a diagnosis of probable AD without any other clinically significant co-morbid pathologies. If there has been a significant change in the subject's clinical status since the last imaging study that is not consistent with progression of the subject's AD, an imaging study should be performed to confirm eligibility
- •Reliable caregiver(s) or informant(s) who attends the subject at least an average of 3 hours or more per day for 3 or more days per week and who will agree to accompany the subject to the clinic visits and reliably complete the caregiver questions
- •Adequate vision and motor function to comply with testing
- •If taking an approved cholinesterase inhibitor for treatment of Alzheimer's disease, must be on a stable dose for at least 3 months prior to entry into study and the dose must not change during the study unless a change is required due to an adverse effect of the prescribed medication or a clinically significant change in the patient's status
- •Subjects who are memantine naïve or have been off memantine for at least 90 days prior to initial treatment with study drug
- •Subjects on neuroleptic medications must be on a stable dose for ≥4 weeks at screening (dose adjustments will be permitted if medically necessary at the discretion of the PI)
- •Females participating in the study must meet one the following criteria:
- •Surgically sterilized (e.g., hysterectomy, bilateral oophorectomy or tubal ligation) for at least 6 months or postmenopausal (postmenopausal females must have no menstrual bleeding for at least 1 year) or
- •If not postmenopausal, agree to use a double method of contraception, one of which is a barrier method (e.g., intrauterine device plus condom, spermicidal gel plus condom) 30 days prior to dosing until 30 days after last dose and have negative human chorionic gonadotropin (β-hCG) test for pregnancy at screening
- •Males who have not had a vasectomy must use appropriate contraception methods (barrier or abstinence) from 30 days prior to dosing until 30 days after last dose
- •In the opinion of the PI subjects should be in reasonably good health over the last 6 months and any chronic disease should be stable -
排除标准
- •Eligibility Criteria:
- •Written informed consent from caregiver and subject (if possible) or legally acceptable representative if different from caregiver
- •Male and female subjects 55-85 years of age inclusive
- •Cognitive deficit present for at least 2 years that meet the diagnostic criteria for probable Alzheimer's dementia. The diagnosis must be confirmed at the time of the screening visit
- •MMSE-2 score of 10-18 inclusive (applies to Screening Visit only)
- •Patients must have a baseline SIB total score of at least 60 and may not have a SIB score >93 at screening
- •Neuroimaging computerized tomography (CT) or Magnetic Resonance Imaging (MRI) within the last 24 months consistent with a diagnosis of probable AD without any other clinically significant co-morbid pathologies. If there has been a significant change in the subject's clinical status since the last imaging study that is not consistent with progression of the subject's AD, an imaging study should be performed to confirm eligibility
- •Reliable caregiver(s) or informant(s) who attends the subject at least an average of 3 hours or more per day for 3 or more days per week and who will agree to accompany the subject to the clinic visits and reliably complete the caregiver questions
- •Adequate vision and motor function to comply with testing
- •If taking an approved cholinesterase inhibitor for treatment of Alzheimer's disease, must be on a stable dose for at least 3 months prior to entry into study and the dose must not change during the study unless a change is required due to an adverse effect of the prescribed medication or a clinically significant change in the patient's status
- •Subjects who are memantine naïve or have been off memantine for at least 90 days prior to initial treatment with study drug
- •Subjects on neuroleptic medications must be on a stable dose for ≥4 weeks at screening (dose adjustments will be permitted if medically necessary at the discretion of the PI)
- •Females participating in the study must meet one the following criteria:
- •Surgically sterilized (e.g., hysterectomy, bilateral oophorectomy or tubal ligation) for at least 6 months or postmenopausal (postmenopausal females must have no menstrual bleeding for at least 1 year) or
- •If not postmenopausal, agree to use a double method of contraception, one of which is a barrier method (e.g., intrauterine device plus condom, spermicidal gel plus condom) 30 days prior to dosing until 30 days after last dose and have negative human chorionic gonadotropin (β-hCG) test for pregnancy at screening
- •Males who have not had a vasectomy must use appropriate contraception methods (barrier or abstinence) from 30 days prior to dosing until 30 days after last dose
- •In the opinion of the PI subjects should be in reasonably good health over the last 6 months and any chronic disease should be stable Exclusion
- •Dementia due to any condition other than AD, including vascular dementia (Rosen-Modified Hachinski Ischemic score ≥ 5)
- •Evidence of significant central nervous system (CNS) vascular disease on previous neuroimaging including but not limited to: cortical stroke, multiple infarcts, localized single infarcts in the thalamus, angular gyrus, multiple lacunar infarcts or extensive white matter injury
- •Clinically significant neurologic disease or condition other than AD, such as cerebral tumor, chronic subdural fluid collections, Huntington's Disease, Parkinson's Disease, normal pressure hydrocephalus, or any other diagnosis that could interfere with assessment of safety and efficacy
- •Evidence of clinically significant unstable cardiovascular, pulmonary, renal, hepatic, gastrointestinal, neurologic, or metabolic disease within the 6 months prior to enrollment. If there is a history of cancer the subject should be clear of cancer for at least 2 years prior to screening. More recent history of basal cell or squamous cell carcinoma and melanoma in situ (Stage 0) may be acceptable after review by the Medical Monitor.
- •Creatinine clearance (CL) of <45ml/min
- •Poorly controlled diabetes, at the discretion of the Principal Investigator
- •Concomitant treatment with NMDA receptor antagonists such as but not limited to memantine or drug combinations containing memantine, dextromethorphan (a cough suppressant), ketamine, phencyclidine (PCP), methoxetamine (MXE), nitrous oxide (N2O) and the following synthetic opioids: penthidine, levorphanol, methadone, dextrpropoxyphene, tramadol, and ketobemidone.
- •Use of vitamin E > 400 International Units (IU) per day within 14 days prior to screening
- •Use of acetaminophen within 14 days prior to screening
- •Use of gabapentin within 14 days prior to screening
- •Use of valproic acid within 14 days prior to screening
- •Use of an active Alzheimer's vaccine within 2 years prior to screening
- •Use of a monoclonal antibody for treatment of AD within 1 year prior to screening
- •Any medical or psychiatric condition that is likely to require initiation of additional medication or surgical intervention during the course of the study
- •Any screening laboratory values outside the reference ranges that are deemed clinically significant by the PI
- •Use of an investigational drug within 90 days prior to screening
- •Suicidality defined as active suicidal thoughts during the 6 months prior to screening or at Baseline [Type 4 or 5 on C-SSRS], or history of suicide attempt in previous 2 years, or at serious suicide risk in PI's judgment
- •Major psychiatric illness such as current major depression according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition , current or past diagnosis of bipolar disorder, schizophrenia, or any other psychiatric disorder that might interfere with the assessments of safety or efficacy at the discretion of the PI
- •Diagnosis of alcohol or drug abuse within the last 2 years
- •Abnormal laboratory tests that suggest an alternate etiology for dementia. If the patient has prior history of serum B12 abnormality, anemia with hemoglobin ≤10g/dl, thyroid function abnormality, electrolyte abnormality, or positive syphilis serology the patient should be revaluated to determine if these potential causes of dementia have been addressed. Only if these causes have been ruled out as the cause of the dementia can the patient be enrolled.
- •History of prolonged QT or prolonged QT on screening ECG (QTcB or QTcF >499 per central reader)
- •Acute or poorly controlled medical illness: blood pressure > 180 mmHg systolic or 100 mmHg diastolic; myocardial infarction within 6 months; uncompensated congestive heart failure [New York Heart Association (NYHA) Class III or IV]
- •Known to be seropositive for human immunodeficiency virus (HIV)
- •Known to be seropositive for Hepatitis B or C, unless successful curative treatment for Hepatitis C (e.g., Harvoni) has been received and there is documentation that there is no Hep B/C virus detected 3 months after completion of treatment
- •AST or ALT >3x upper limit of normal (ULN) and total bilirubin >2x ULN or International Normalized Ratio (INR) >1.5
- •Prior exposure to bryostatin, or known sensitivity to bryostatin or any ingredient in the study drug
- •Any other concurrent medical condition, which in the opinion of the PI makes the subject unsuitable for the clinical study -
研究组 & 干预措施
Bryostatin 1
Active Comparator
20ug Bryostatin will be administered over 45 minutes IV. The course of treatment will include 7 doses over the first 12 weeks, followed by a second identical treatment period beginning 30 days after completion of the first treatment period.
干预措施: Bryostatin 1 (Drug)
Placebo
Placebo Comparator
Placebo will be administered over 45 minutes IV. The course of treatment will include 7 doses over the first 12 weeks, followed by a second identical treatment period beginning 30 days after completion of the first treatment period.
干预措施: Placebo (Other)
结局指标
主要结局
Safety: Treatment-emergent Adverse Events and Serious Adverse Events for All Randomized Subjects Who Received Any Study Medication
时间窗: Prior to version 6 of the protocol, final assessments were performed at Week 42, 12 weeks after the last study treatment. The final study visit took place at Week 30 for subjects remaining in the study after the protocol amendment.
Treatment emergent adverse events and serious adverse events will be analyzed by treatment group.
Efficacy: Severe Impairment Battery Total Score Assessment Obtained After Completion of the Second Couse of Treatment (Week 28)
时间窗: Primary efficacy analysis at Week 28
The treatment difference in the primary efficacy endpoint of Severe Impairment Battery (SIB). The SIB is used to assess cognition in subjects with moderate and severe AD. It is divided into nine subscales that include attention, language, orientation, memory, praxis, visuospatial ability, construction, social skills, orienting head to name. Non-verbal responses are allowed, thus decreasing the need for language output. Forty questions are included with a point score range of 0-100. Lower scores indicate greater cognitive impairment.
次要结局
- The Changes From Baseline in SIB Total Scores at Weeks 9, 20, 24, and 30(Weeks 9, 20 and 24 occur during the treatment phase of the study. Week 30 occurred 4 weeks after end of treatment.)
- Severe Impairment Battery (SIB) Total Score at the End of the Week 42 Follow-up Visit(Week 42 was the final follow-up for study subjects, occurring 16 weeks after the last dose of study drug. Subjects who remained in the study at the time version 6 of the protocol was implemented did not have Week 42 visit.)
- The SIB Total Score From Baseline at Week 13(Week 13 followed the first 12-week course of study treatment.)
- SIB Total Scores From Baseline at Weeks 9, 20, 24 and 30 for Subjects With Baseline Mini Mental State Exam Version 2 (MMSE-2) Scores of 10-14 and 15-18(Weeks 9, 20, 24 and 30)
- SIB Trends Over Time(Slopes will be estimated by using SIB data at Week 0, 5, 9, 13, 15, 20, 24, and 28)
研究者
研究点 (19)
Loading locations...
相似试验
Unknown
2 期
Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's DiseaseAlzheimer's DiseaseNCT00606164Blanchette Rockefeller Neurosciences Insitute9
已完成
2 期
A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's DiseaseAlzheimer's DiseaseNCT02431468Neurotrope Bioscience, Inc.147
已完成
2 期
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On MemantineAlzheimer DiseaseNCT03560245Neurotrope Bioscience, Inc.108
已完成
1 期
Bryostatin and Vincristine in B-Cell MalignanciesRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Multiple MyelomaStage III Multiple MyelomaNCT00003166National Cancer Institute (NCI)18
已完成
2 期
BTRX-246040 Study in Participants With Parkinson's Disease With Motor FluctuationsMotor DisorderParkinson DiseaseNCT03608371BlackThorn Therapeutics, Inc.24